There is a huge gap between the reported incidence of side-effects in the medical literature most of the studies sponsored by the drug manufactures and the apparent prevalence in the general population
As GLP1 medications become increasingly common for diabetes management and weight loss, questions have emerged about whether they influence the risk of developing kidney stones
3rd GLP-1 Based Therapeutics Summit 2026 14th April 2026 - April 16, 2026 The 3rd GLP-1 Based Therapeutics Summit is the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications
This could lead to new ways to identify and treat aggressive melanoma
When combining GLP-1 receptor agonists with insulin or sulfonylureas, the chance of experiencing hypoglycemia (low blood sugar) goes up
While rare, more serious conditions like pancreatitis require prompt evaluation and cannot be self-managed